New treatment options for advanced pancreatic cancer

Middleton, Gary; Ghaneh, Paula; Costello, Eithne; Greenhalf, William; Neoptolemos, John P.

doi:10.1586/17474124.2.5.673

Cited by 31 publications

(20 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is a new generation drug guided on the basis of the antigen/antibody affinity. It is a humanized monoclonal antibody used for blocking vascular endothelial growth factor A and is regarded as an angiogenesis inhibitor [20,21].…”

Section: Discussionmentioning

confidence: 99%

Inhibition of cysteine peptidase activity in ascitic fluid in pancreatic cancer patients.

Agrawal

Kielan²,

Katib³

et al. 2011

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Abstract:The work's objective is to answer the question whether there is any possibility of activity inhibition of cysteine peptidases inhibitors playing an important role in key processes accompanying cancer formation, including pancreas. There is a justified speculation that specific inhibitors of these enzymes may inhibit development of cancer processes by inhibiting their activity. In vitro studies confirmed that these enzymes in ascitic fluid were inhibited with egg whites inhibitors even to 90% of their original activity.

show abstract

Section: Discussionmentioning

confidence: 99%

Inhibition of cysteine peptidase activity in ascitic fluid in pancreatic cancer patients.

Agrawal

Kielan²,

Katib³

et al. 2011

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

show abstract

“…Akt, a major downstream target of PI3K, was originally reported as the cellular counterpart of the viral oncogene, which was amplified in gastric adenocarcinoma [14] . Overexpression of Akt isoforms has now been reported in ovarian, breast, prostate, and pancreatic cancers [16,[33][34][35] . In addition, Akt activity is increased in cancers where the PTEN tumor suppressor is mutated [36] .…”

Section: Discussionmentioning

confidence: 99%

Alisol B acetate induces apoptosis of SGC7901 cells via mitochondrial and phosphatidylinositol 3-kinases/Akt signaling pathways

Xu¹,

Zhao²,

Li³

2009

WJG

View full text Add to dashboard Cite

AIM:To examine the effect of alisol B acetate on the growth of human gastric cancer cell line SGC7901 and its possible mechanism of action. METHODS:The cytotoxic effect of alisol B acetate on SGC7901 cells was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Phase-contrast and electron microscopy were used to observe the morphological changes. Cell cycle and mitochondrial transmembrane potential (ΔΨm) were determined by flow cytometry. Western blotting was used to detect the expression of apoptosis-regulated gene Bcl-2, Bax, Apaf-1, caspase-3, caspase-9, Akt, P-Akt and phosphatidylinositol 3-kinases (PI3K). RESULTS:Alisol B acetate inhibited the proliferation of SGC7901 cell line in a time-and dose-dependent manner. PI staining showed that alisol B acetate can change the cell cycle distribution of SGC7901, increase the proportion of cells in G0-G1 phase and decrease the proportion of S phase cells and G2-M phase cells. Alisol B acetate at a concentration of 30 μmol/L induced apoptosis after 24, 48 and 72 h incubation, with occurrence rates of apoptotic cells of 4.36%, 14.42% and 21.16%, respectively. Phase-contrast and electron microscopy revealed that the nuclear fragmentation and chromosomal condensed, cells shrank and attachment loss appeared in the SGC7901 treated with alisol B acetate. Apoptosis of SGC7901 cells was associated with cell cycle arrest, caspase-3 and caspase-9 activation, loss of mitochondrial membrane potential and up-regulation of the ratio of Bax/Bcl-2 and inhibition of the PI3K/Akt. CONCLUSION:Alisol B acetate exhibits an antiproliferative effect in SGC7901 cells by inducing apoptosis. Apoptosis of SGC7901 cells involves mitochondria-caspase and PI3K/Akt dependent pathways.

show abstract

“…84 Currently, the standard of care for advanced pancreatic cancer is the chemotherapeutic drug gemcitabine. 85 Clinical trials of allogeneic vaccines for pancreatic cancer are currently underway and the early phase of trials have reported promising results. Two allogeneic vaccines in currently tested in clinical trials for the treatment of pancreatic cancer include NewLink Genetic's HyperAcute® pancreatic cancer vaccine (Algenpantucel-L) and BioSante Pharmaceutical's GVAX Pancreas Vaccine.…”

Section: Pancreatic Cancermentioning

confidence: 99%